The pros and cons to using a dry powder inhaler as treatment for chronic obstructive pulmonary disease. Neil Minkoff, MD: Dr Drummond, we’ve talked a little bit about the differences. You brought some ...

Aptar Pharma pulled the trigger on a deal for Pharmaxis’ Orbital high payload dry powder inhaler technology, paying $2.5 million for a worldwide license with the same again to follow if it chooses to ...

Respiratory inhaler devices are essential tools for delivering medication directly into the lungs for the treatment and management of respiratory conditions such as asthma, chronic obstructive ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jck8xq/dry_powder) has announced the addition of the "Dry Powder Inhalers to ...

The characteristics of an ideal inhaler are based around the design and formulation of the device, patient use and the clinical effect, together with concordance and patient preference. To ensure ...

ST. PAUL, Minn.--(BUSINESS WIRE)--Kindeva Drug Delivery L.P. (Kindeva) and Cambridge Healthcare Innovations Limited (CHI) have entered into a collaboration to develop and commercialize CHI’s αeolus ...

Neil Minkoff, MD: That’s such an important aspect in terms of balancing what’s right for each patient. I’m going to pull Dr Drummond in here to comment on that further. We started touching on the idea ...

Background and Goal: This study examined whether patients with non-reversible chronic airway disease using a transparent capsule in single-dose dry powder inhalers affects the amount of medication ...

The global aerosol delivery devices market size was US$ 14.5 billion in 2021. The global aerosol delivery devices market is forecast to grow to US$ 21.1 billion by 2030 by growing at a compound annual ...

The flurry of business development activity at Aptar continues. Having made moves for injectable drug delivery and digital therapeutic players in recent weeks, Aptar has now nabbed (PDF) an option on ...